Kura Oncology’s fair value estimate has been adjusted from US$32.27 to US$31.08, a small move that still reflects detailed ...
Idorsia’s analyst story has shifted again, with a new CHF 5 price target sitting alongside an unchanged fair value estimate of CHF 4.5. This reset reflects a mix of confidence in the company’s assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results